Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?
about
Analysis of polymorphisms and haplotype structure of the human thymidylate synthase genetic region: a tool for pharmacogenetic studiesdCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells.Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment.5-Fluorouracil derivatives: a patent review.Transcriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression.Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cellsReexamining a proposal: thymidylate synthase 5'-untranslated region as a regulator of translation efficiency.Delimiting Allelic Imbalance of TYMS by Allele-Specific AnalysisPrognostic significance of miR-215 in colon cancer.A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosingABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer.5-fu metabolism in cancer and orally-administrable 5-fu drugs.Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy.Beyond Thymidylate Synthase and Dihydrofolate Reductase: Impact of Non-coding microRNAs in Anticancer Chemoresistance.Implications of miRNAs in Colorectal Cancer Chemoresistance.MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy.Cellular response to efficient dUTPase RNAi silencing in stable HeLa cell lines perturbs expression levels of genes involved in thymidylate metabolism.Identification of thymidylate synthase as a potential therapeutic target for lung cancer.Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence.Molecular features that predict the response to antimetabolite chemotherapies.E2F1/TS Immunophenotype and Survival of Patients with Colorectal Cancer Treated with 5FU-Based Adjuvant Therapy.Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy.Drug resistance and new therapies in colorectal cancer
P2860
Q28482151-7352F9C7-24BD-4C2F-B4CC-F18610F5FB13Q33727842-C7AEAFE1-E273-47A4-90E2-B21B5D2E56BDQ33895297-FFF96ECD-1B05-451D-B3F8-AEE9F494DD97Q33914197-EED8A506-31FC-4EA3-9510-E0995708570BQ34253978-E58B674E-C940-4370-85F1-2B41AB5ADE52Q34443004-11E55F91-97FC-4FD9-A9E0-49743FAFB437Q34890054-108D721B-135B-4AB1-81DF-190ADA6928F6Q35556789-6603F2FF-1E43-4756-91D6-7B74A878B050Q35858190-FBE86ADC-F4ED-479E-932A-99CA5D993F0AQ36077545-9A1016D8-8BE5-400D-BF26-CB355D9F37C5Q36236475-ADA364D2-75C4-4777-86C8-5AE0E9A867D0Q36413318-2D5F9D8F-B38C-41C5-B6ED-212B5509055FQ37334281-B22C4F04-4A65-477D-90C4-48DF518A4BF0Q37414536-23BB41C1-EA22-494C-8348-87F22297CF86Q38200600-E3278F0E-4FCA-4834-A3F8-15C0DD36EA04Q38370358-21A671C1-60C7-480B-A26B-89D2AAA9AAC4Q39390383-2290DFDA-6A81-4237-AF15-98AB32A66B38Q39502512-3DE4094A-0F2F-4E2E-9D98-115DE3AE1B87Q39680552-33C62EDC-E28C-4C9C-8697-E3B62EE46872Q39893194-A1079A95-FED3-403B-BCE9-9C01640CFA0CQ42281145-34253310-F4B9-4107-8830-8FD3684831ACQ42748851-CE353B0D-DEEA-4BA9-A044-961DD878EEFFQ43053804-AFA3ED90-BF7C-4EA0-8B91-6EC689492928Q54394304-39A7D223-0530-413E-AC21-289714F2E0E6Q58740344-42CA3F06-E21C-4966-A3B6-38FEE8939376
P2860
Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Evaluating the drug-target rel ...... l. Is it time to move forward?
@ast
Evaluating the drug-target rel ...... l. Is it time to move forward?
@en
Evaluating the drug-target rel ...... l. Is it time to move forward?
@nl
type
label
Evaluating the drug-target rel ...... l. Is it time to move forward?
@ast
Evaluating the drug-target rel ...... l. Is it time to move forward?
@en
Evaluating the drug-target rel ...... l. Is it time to move forward?
@nl
prefLabel
Evaluating the drug-target rel ...... l. Is it time to move forward?
@ast
Evaluating the drug-target rel ...... l. Is it time to move forward?
@en
Evaluating the drug-target rel ...... l. Is it time to move forward?
@nl
P2093
P2860
P356
P1476
Evaluating the drug-target rel ...... l. Is it time to move forward?
@en
P2093
Agnes Witkiewicz
Charles J Yeo
Eugene P Kennedy
Jonathan R Brody
Robert Havens
Scott E Kern
Shayna L Showalter
Tomas Hucl
P2860
P304
P356
10.4161/CBT.7.7.6181
P577
2008-04-21T00:00:00Z